

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.org) on Apr 17, 2025

BxPC-3

RRID:CVCL_0186

Type: Cell Line

Proper Citation

(RRID:CVCL_0186)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0186

Proper Citation: (RRID:CVCL_0186)

Sex: Female

Defining Citation: [PMID:1630814](#), [PMID:1764370](#), [PMID:3754176](#), [PMID:7961102](#), [PMID:8026879](#), [PMID:8194712](#), [PMID:8286197](#), [PMID:8426738](#), [PMID:9788440](#), [PMID:10027410](#), [PMID:10408907](#), [PMID:11115575](#), [PMID:11169959](#), [PMID:12692724](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15688027](#), [PMID:16912165](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20418756](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27073551](#), [PMID:27229158](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:27910856](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32782605](#), [PMID:35839778](#)

Comments: Caution: Additional TP53 mutation in c.793C>T indicated incorrectly in PubMed=1630814., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: Metabolome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: BxPC-3

Synonyms: BxPc-3, BXPC-3, Bx-PC3, BXPC3, BxPC3, BxPc3, Biopsy xenograft of Pancreatic Carcinoma line-3

Cross References: BTO:BTO_0001861, CLO:CLO_0002065, EFO:EFO_0002709, MCCL:MCC:0000077, CLDB:cl516, CLDB:cl517, CLDB:cl518, AddexBio:C0018003/27, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1687, BCRC:60283, BCRJ:0056, BioGRID_ORCS_Cell_line:162, BioSample:SAMN03470942, BioSample:SAMN10987955, cancercellines:CVCL_0186, CCRID:1101HUM-PUMC000274, CCRID:3101HUMTCHu012, Cell_Model_Passport:SIDM00132, CGH-DB:161-1, CGH-DB:9272-4, ChEMBL-Cells:ChEMBL3307637, ChEMBL-Targets:ChEMBL614530, CLS:305031, Cosmic:707248, Cosmic:730531, Cosmic:736269, Cosmic:755301, Cosmic:808164, Cosmic:872995, Cosmic:906693, Cosmic:913310, Cosmic:918055, Cosmic:922251, Cosmic:923165, Cosmic:932515, Cosmic:933516, Cosmic:947403, Cosmic:948372, Cosmic:949321, Cosmic:968108, Cosmic:1006369, Cosmic:1198209, Cosmic:1299295, Cosmic:1366281, Cosmic:1477430, Cosmic:1518232, Cosmic:1534316, Cosmic:1571773, Cosmic:1644317, Cosmic:1768263, Cosmic:1945873, Cosmic:2434095, Cosmic:2820476, Cosmic-CLP:906693, DepMap:ACH-000535, DSMZ:ACC-760, DSMZCellDive:ACC-760, ECACC:93120816, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906693, GEO:GSM206447, GEO:GSM621894, GEO:GSM784699, GEO:GSM886896, GEO:GSM887961, GEO:GSM1024397, GEO:GSM1374415, GEO:GSM1374416, GEO:GSM1374417, GEO:GSM1588608, GEO:GSM1588620, GEO:GSM1669634, GEO:GSM1906991, GEO:GSM1906992, GEO:GSM1906993, IARC_TP53:312, ICLC:HTL96011, IZSLER:BS TCL 4, KCB:KCB 200428YJ, LiGeA:CCLE_491, LINCS_LDP:LCL-1731, Lonza:1013, PharmacDB:BxPC3_149_2019, PRIDE:PXD003198, PRIDE:PXD030304, PRIDE:PXD032263, Progenetix:CVCL_0186, PubChem_Cell_line:CVCL_0186, SKY/M-FISH/CGH:1995, TOKU-E:707, Ubigen:YC-C015, Wikidata:Q54798758

ID: CVCL_0186

Record Creation Time: 20220427T215417+0000

Record Last Update: 20250131T100224+0000

Ratings and Alerts

No rating or validation information has been found for BxPC-3.

No alerts have been found for BxPC-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1245 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Zheng JH, et al. (2024) A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. *Cell reports*, 43(8), 114633.

Moreno P, et al. (2024) ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. *bioRxiv : the preprint server for biology*.

Wang Y, et al. (2024) Inhibition of autophagy induced by tetrandrine promotes the accumulation of reactive oxygen species and sensitizes efficacy of tetrandrine in pancreatic cancer. *Cancer cell international*, 24(1), 241.

Ohara Y, et al. (2024) LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. *Carcinogenesis*.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. *Cell reports*, 43(5), 114202.

Wehrli M, et al. (2024) Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1859.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.

Long AW, et al. (2024) Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. *Journal of hematology & oncology*, 17(1), 20.

Wang T, et al. (2024) Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF- κ B/GLUT1 and SREBP1 pathways. *iScience*, 27(5), 109741.

Furuya-Ikude C, et al. (2024) NCF-1 plays a pivotal role in the survival of adenocarcinoma cells of pancreatic and gastric origins. *In vitro cellular & developmental biology. Animal*, 60(10), 1151.

Alors-Pérez E, et al. (2024) Spliceosomal dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets. *Molecular oncology*, 18(10), 2524.

Chang Y, et al. (2024) The UBE2F-CRL5ASB11-DIRAS2 axis is an oncogene and tumor suppressor cascade in pancreatic cancer cells. *Developmental cell*, 59(10), 1317.

Sneider A, et al. (2024) Small Extracellular Vesicles Promote Stiffness-mediated Metastasis. *Cancer research communications*, 4(5), 1240.

Savage SR, et al. (2024) Pan-cancer proteogenomics expands the landscape of therapeutic targets. *Cell*, 187(16), 4389.

Schäfer TE, et al. (2024) Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. *EBioMedicine*, 105, 105219.

Wang W, et al. (2024) BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis. *Cancers*, 16(8).

Wang K, et al. (2024) Multi-Algorithm Analysis Reveals Pyroptosis-Linked Genes as Pancreatic Cancer Biomarkers. *Cancers*, 16(2).

Girolimetti G, et al. (2024) Dysregulation of a Subset of Circulating and Vesicle-Associated miRNA in Pancreatic Cancer. *Non-coding RNA*, 10(3).

Tao J, et al. (2024) CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. *Journal of experimental & clinical cancer research : CR*, 43(1), 277.

Saleh H, et al. (2024) KH-like Domains in PARP9/DTX3L and PARP14 Coordinate Protein-Protein Interactions to Promote Cancer Cell Survival. *Journal of molecular biology*, 436(4), 168434.